AnaptysBio (ANAB) Stock: Buy, Sell, or Hold?
$48.60
-0.17 (-0.35%)
âŧ
5d:
+6.63%
30d:
+4.14%
90d:
-16.88%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (72%)
Quality Score
53/100
Position
SLIGHTLY HIGH
30-Day Fair Range
$46.28 â $49.01
Position: SLIGHTLY HIGH
Forward P/E & Valuation
10.8x
FAIR
vs 10.8x historical avg
Wall Street Target
$87.25
+78.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$45.01 / $49.16
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: ANAB is fairly priced but lacks strong directional signals. At -0.2% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Get Alerted When ANAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$65.72
Based on 6.1% avg growth
INTRINSIC VALUE TODAY
$40.81
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ANAB is currently trading at $48.60, which is considered slightly high relative to its 30-day fair value range of $46.28 to $49.01. The stock's valuation (Forward PE: 10.8) is in line with its historical norms (10.8). Remarkably, the market is currently pricing in an annual earnings decline of 0.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ANAB is in a strong downtrend. The price is approaching resistance at $49.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $87.25 (+78.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ANAB is in a strong downtrend. The price is approaching resistance at $49.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $87.25 (+78.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$46.28 -
$49.01
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.9%
Trading Range & Key Levels
30-Day Trading Range
$46.28 -
$49.01
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$6.49
(13.3%)
Support Level
$45.01
Resistance Level
$49.16
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (47/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 78.9% below Wall St target ($87.25)
- WARNING: Composite score 53/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
10.75
Wall Street Target
$87.25
(+78.9%)
Revenue Growth (YoY)
23.5%
Profit Margin
247.0%
Valuation Discount vs History
-0.2% cheaper
PE vs Historical
10.8 vs 10.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.2%
(market-implied from PE analysis)
1-Year Target
$48.67
(0%)
2-Year Target
$48.58
(0%)
3-Year Target
$48.48
(-1%)
3-Yr Target (if PE normalizes)
(PE: 11â11)
$48.72
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 8.1%)
$113.93
(+134%)
Base:
(SPY PE: 10.7, Growth: 8.1%)
$61.64
(+26%)
Bear:
(PE: 9.1, Growth: 8.1%)
$52.40
(+7%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.7 to 10.8
Stabilization Target:
$49.02
(+0.5%)
PE Expansion Potential:
+0.5%
Share ANAB Analysis
Share this live ANAB analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ANAB)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Investors are expressing optimism on social media regarding the outcome of the legal dispute between AnaptysBio and TESARO. No recent news articles provide new information on the situation.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$91 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 52 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 50 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ANAB Research Pages